enavatuzumab
mAbexperimental
Enavatuzumab is a humanized monoclonal antibody used in the treatment of solid tumors. It targets the TWEAK receptor. — Wikipedia
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 1, 2008 (NCT00738764)
Timeline
Indications
Mechanism of action
TNFRSF12A agonist
Activates the NF¿B pathway, and that its growth inhibitory activity is dependent on NF¿B.
TNFSF12 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaEnavatuzumab ↗
- ChEMBLCHEMBL2109597 ↗
- ChEMBLCHEMBL1743011 ↗
Also known as
- anti-tweak
- enavatuzumab
- pdl192
- pdl-192
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07190261 | Phase 2 | Sep 18, 2025 | Chinese Academy of Medical Sciences |
| NCT00738764 | Phase 1 | Jul 1, 2008 | Abbott |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Abbott | For profit | 1 | 1 | 1 | 2008 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1